Skip to main content

Markets News Screener Research Editorials Pricing About

⌘K

Sign in Start free

Not investment advice. Moatkeep provides data and educational content, not recommendations.

Financial glossary·Pricing·About·Disclaimer·Terms·Privacy·Cookies·Methodology·Support·Company directory·Feed

© moatkeep 2026

Gevo, Inc. (GEVO) stock — financials, valuation and filings | Moatkeep

Companies/Nasdaq/GEVO

Gevo, Inc.

GEVO · Nasdaq

$1.57−1.26%

Close, 2026-09-15Close, 2026-09-15 · source: Databento · USD · figures not investment advice

Window -76.5%vs low +215.3%vs high -79.6%

Pricethrough 2026-09-15ex-date (0) · fiscal quarter (0)

Dividends: company filings (SEC EDGAR) and the historical exchange record.

State of incorporation: DE
Fiscal year end: Dec 31

Valuation snapshot

$356.02M

N/M

1.30

—

-63.18%

-15.91%

Close, 2026-08-06

Financials · five yearsInvestor

Revenue•••••••••••••••

Gross profit•••••••••••••••

Operating income•••••••••••••••

Net income•••••••••••••••

Free cash flow•••••••••••••••

Investor

Read the full financial statements

Free accounts read five years of annual financials.

Source: SEC EDGAR (XBRL) · figures in USD millions

Related companies

IPSC — Century Therapeutics, Inc.NATR — NATURES SUNSHINE PRODUCTS INC CIX — COMPX INTERNATIONAL INC ZNTL — Zentalis Pharmaceuticals, Inc.CMPX — Compass Therapeutics, Inc.DMAC — DiaMedica Therapeutics Inc.STRO — SUTRO BIOPHARMA, INC.RR — RICHTECH ROBOTICS INC.